Literature DB >> 9869999

Ventricular performance and quality of life in patients who underwent radiofrequency AV junction ablation and permanent pacemaker implantation due to medically refractory atrial tachyarrhythmias.

A G Manolis1, A G Katsivas, E E Lazaris, C V Vassilopoulos, N E Louvros.   

Abstract

UNLABELLED: In patients with drug refractory atrial tachyarrhythmias and previous failed attempts of ablation of the arrhythmia substrate, radiofrequency (RF) modulation or ablation of the atrioventricular (AV) junction is an alternative procedure. AIM: Of this study was to assess the efficacy and long term results of RF AV junction ablation in conjunction with permanent pacemaker implantation, in the management of patients with drug resistant atrial tachyarrhythmias.
METHODS: Between 4/92 and 1/97, 46 patients (30 male, 16 female, 67 +/- 12 years) underwent RF AV junction ablation because of paroxysmal atrial fibrillation (24 patients), chronic atrial fibrillation (13 patients), atrial flutter (5 patients) and atrial tachycardia (4 patients). The underlying heart disease was dilated cardiomyopathy (16), ischemic heart disease (9), hypertensive heart disease (6), hypertrophic cardiomyopathy (3), atrial septal defect (2) and non structural heart disease (10). The duration of symptoms was 6.4 +/- 3.5 years at a maximal heart rate 169 +/- 24 bpm. The hospital admissions in the last 12 months were 8.2 +/- 3 per patient. The failed antiarrhythmic drugs were 3.5 +/- 2.1. The functional NYHA class was 2.7 +/- 0.6. Patients with atrial flutter and atrial tachycardia had previous failed attempts of RF ablation of the arrhythmia substrate. Thirty patients had a compromised left ventricular systolic function with LVEF below 50% (mean 34 +/- 9%). AV junction ablation was achieved in all patients after 4 +/- 2.5 RF applications. Post ablation, the selected pacing mode was DDD-R for the 33 patients with paroxysmal atrial tachyarrhythmias and VVI-R for the 13 pts with chronic atrial fibrillation. The dual chamber pacemakers implanted had the option of automatic mode switch.
RESULTS: During the follow-up period of 28 +/- 13 months (6-47), AV conduction recovered in 1 patient. Antiarrhythmic treatment was necessary in only 7 patients. Post ablation the new functional NYHA class was 1.4 +/- 0.8 (p < 0.001). Post ablation hospital admissions, including ordinary pacemaker follow-up visits, were 4 +/- 1 per patient per year (p < 0.001). Six months after the procedure the LVEF of the study population was increased from 42 +/- 16% to 50 +/- 14% (p = NS). In the 30 patients with heart failure the LVEF was significantly increased to 46 +/- 8% (p < 0.05). Symptomatic relief or significant improvement was observed in all patients as showed by the answers given in a customized questionnaire before and after the procedure.
CONCLUSIONS: In patients with drug refractory atrial tachyarrhythmias, RF AV junction ablation and permanent pacemaker implantation is an alternative therapy with excellent long term results in terms of arrhythmia control, ventricular performance and quality of life.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9869999     DOI: 10.1023/a:1009721008761

Source DB:  PubMed          Journal:  J Interv Card Electrophysiol        ISSN: 1383-875X            Impact factor:   1.900


  19 in total

1.  Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy.

Authors:  M Grogan; H C Smith; B J Gersh; D L Wood
Journal:  Am J Cardiol       Date:  1992-06-15       Impact factor: 2.778

2.  Effect of an irregular ventricular rhythm on cardiac output.

Authors:  E G Daoud; R Weiss; M Bahu; B P Knight; F Bogun; R Goyal; M Harvey; S A Strickberger; K C Man; F Morady
Journal:  Am J Cardiol       Date:  1996-12-15       Impact factor: 2.778

3.  Impact on ventricular function and quality of life of transcatheter ablation of the atrioventricular junction in chronic atrial fibrillation with a normal ventricular response.

Authors:  A Natale; L Zimerman; G Tomassoni; M Kearney; V Kent; M J Brandon; K Newby
Journal:  Am J Cardiol       Date:  1996-12-15       Impact factor: 2.778

4.  Reversibility of tachycardia-induced left ventricular dysfunction after closed-chest catheter ablation of the atrioventricular junction for intractable atrial fibrillation.

Authors:  R Lemery; P Brugada; E Cheriex; H J Wellens
Journal:  Am J Cardiol       Date:  1987-12-01       Impact factor: 2.778

5.  Quality of life and outcomes after radiofrequency His-bundle catheter ablation and permanent pacemaker implantation: impact of treatment in paroxysmal and established atrial fibrillation.

Authors:  A P Fitzpatrick; H D Kourouyan; A Siu; R J Lee; M D Lesh; L M Epstein; J C Griffin; M M Scheinman
Journal:  Am Heart J       Date:  1996-03       Impact factor: 4.749

6.  Influence of atrioventricular junction radiofrequency ablation in patients with chronic atrial fibrillation and flutter on quality of life and cardiac performance.

Authors:  M Brignole; L Gianfranchi; C Menozzi; N Bottoni; R Bollini; G Lolli; D Oddone; G Gaggioli
Journal:  Am J Cardiol       Date:  1994-08-01       Impact factor: 2.778

7.  Effects on cardiac performance of atrioventricular node catheter ablation using radiofrequency current for drug-refractory atrial arrhythmias.

Authors:  N Twidale; K Sutton; L Bartlett; A Dooley; S Winstanley; W Heddle; R Hassam; H Koutsounis
Journal:  Pacing Clin Electrophysiol       Date:  1993-06       Impact factor: 1.976

8.  Initial experience with a new algorithm for automatic mode switching from DDDR to DDIR mode.

Authors:  I E Ovsyshcher; A Katz; C Bondy
Journal:  Pacing Clin Electrophysiol       Date:  1994-11       Impact factor: 1.976

9.  Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators.

Authors:  G C Flaker; J L Blackshear; R McBride; R A Kronmal; J L Halperin; R G Hart
Journal:  J Am Coll Cardiol       Date:  1992-09       Impact factor: 24.094

10.  The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.

Authors:  M Packer; M R Bristow; J N Cohn; W S Colucci; M B Fowler; E M Gilbert; N H Shusterman
Journal:  N Engl J Med       Date:  1996-05-23       Impact factor: 91.245

View more
  20 in total

Review 1.  Computational approaches to structural and functional analysis of plastocyanin and other blue copper proteins.

Authors:  F De Rienzo; R R Gabdoulline; R C Wade; M Sola; M C Menziani
Journal:  Cell Mol Life Sci       Date:  2004-05       Impact factor: 9.261

2.  Frequency and predictors of tachycardia-induced cardiomyopathy in patients with persistent atrial flutter.

Authors:  Stephen Pizzale; Robert Lemery; Martin S Green; Michael H Gollob; Anthony S L Tang; David H Birnie
Journal:  Can J Cardiol       Date:  2009-08       Impact factor: 5.223

Review 3.  Treatment Considerations for a Dual Epidemic of Atrial Fibrillation and Heart Failure.

Authors:  Parikshit S Sharma; David J Callans
Journal:  J Atr Fibrillation       Date:  2013-08-31

Review 4.  Atrial Fibrillation and Heart Failure: A Review of the Intersection of Two Cardiac Epidemics.

Authors:  Kay Lee Park; Elad Anter
Journal:  J Atr Fibrillation       Date:  2013-06-30

5.  Reversal of cardiomyopathy in patients with congestive heart failure secondary to tachycardia.

Authors:  Zhao Donghua; Peng Jian; Xiao Zhongbo; Zhang Feifei; Peng Xinhui; Yang Hao; Liu Fuqiang; Li Yan; Xie Yong; Huang Xinfu; Meng Surong; Wu Muli; Xu Dingli
Journal:  J Interv Card Electrophysiol       Date:  2012-10-23       Impact factor: 1.900

6.  Atrial fibrillation exacerbates cognitive dysfunction and cerebral perfusion in heart failure.

Authors:  Michael L Alosco; Mary Beth Spitznagel; Lawrence H Sweet; Richard Josephson; Joel Hughes; John Gunstad
Journal:  Pacing Clin Electrophysiol       Date:  2014-12-10       Impact factor: 1.976

7.  Atrioventricular Nodal Catheter Ablation in Atrial Fibrillation Complicating Congestive Heart Failure.

Authors:  Osmar Antonio Centurión; Karina Elizabeth Scavenius; Laura B García; Luis Miño; Judith Torales; Orlando Sequeira
Journal:  J Atr Fibrillation       Date:  2018-06-30

8.  Atrial fibrillation in patients with heart failure: Role of catheter ablation therapies.

Authors:  Nasir Shariff; Abdul Aleem; Vadim Levin; Mukesh Singh; Nauman Islam; Ronald Freudenberger
Journal:  Exp Clin Cardiol       Date:  2012

Review 9.  Heart failure and tachycardia-induced cardiomyopathy.

Authors:  Ethan R Ellis; Mark E Josephson
Journal:  Curr Heart Fail Rep       Date:  2013-12

Review 10.  [Rate versus rhythm control with and without heart failure].

Authors:  Florian Straube; Uwe Dorwarth; Sabine Janko; Ellen Hoffmann
Journal:  Herz       Date:  2008-12       Impact factor: 1.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.